These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38150626)

  • 1. DrugGen: a database of de novo-generated molecular binders for specified target proteins.
    Qian H; Zhou J; Tu S; Xu L
    Database (Oxford); 2023 Dec; 2023():. PubMed ID: 38150626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MolAICal: a soft tool for 3D drug design of protein targets by artificial intelligence and classical algorithm.
    Bai Q; Tan S; Xu T; Liu H; Huang J; Yao X
    Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32778891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Artificial Intelligence in
    Kumar R; Sharma A; Alexiou A; Ashraf GM
    Curr Top Med Chem; 2022; 22(30):2483-2492. PubMed ID: 36263480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolving scenario of big data and Artificial Intelligence (AI) in drug discovery.
    Tripathi MK; Nath A; Singh TP; Ethayathulla AS; Kaur P
    Mol Divers; 2021 Aug; 25(3):1439-1460. PubMed ID: 34159484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. De novo generation of dual-target ligands using adversarial training and reinforcement learning.
    Lu F; Li M; Min X; Li C; Zeng X
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34410338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Artificial intelligence: Machine learning approach for screening large database and drug discovery.
    Parvatikar PP; Patil S; Khaparkhuntikar K; Patil S; Singh PK; Sahana R; Kulkarni RV; Raghu AV
    Antiviral Res; 2023 Dec; 220():105740. PubMed ID: 37935248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. REINVENT 2.0: An AI Tool for De Novo Drug Design.
    Blaschke T; Arús-Pous J; Chen H; Margreitter C; Tyrchan C; Engkvist O; Papadopoulos K; Patronov A
    J Chem Inf Model; 2020 Dec; 60(12):5918-5922. PubMed ID: 33118816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent trends in artificial intelligence-driven identification and development of anti-neurodegenerative therapeutic agents.
    Kashyap K; Siddiqi MI
    Mol Divers; 2021 Aug; 25(3):1517-1539. PubMed ID: 34282519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concepts of Artificial Intelligence for Computer-Assisted Drug Discovery.
    Yang X; Wang Y; Byrne R; Schneider G; Yang S
    Chem Rev; 2019 Sep; 119(18):10520-10594. PubMed ID: 31294972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generative machine learning for de novo drug discovery: A systematic review.
    Martinelli DD
    Comput Biol Med; 2022 Jun; 145():105403. PubMed ID: 35339849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generating and screening de novo compounds against given targets using ultrafast deep learning models as core components.
    Zhang H; Saravanan KM; Yang Y; Wei Y; Yi P; Zhang JZH
    Brief Bioinform; 2022 Jul; 23(4):. PubMed ID: 35724626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Artificial Intelligence, Machine Learning, and Deep Learning in Real-Life Drug Design Cases.
    Muller C; Rabal O; Diaz Gonzalez C
    Methods Mol Biol; 2022; 2390():383-407. PubMed ID: 34731478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the artificial intelligence and machine learning models in the context of drug design difficulties and future potential for the pharmaceutical sectors.
    Shiammala PN; Duraimutharasan NKB; Vaseeharan B; Alothaim AS; Al-Malki ES; Snekaa B; Safi SZ; Singh SK; Velmurugan D; Selvaraj C
    Methods; 2023 Nov; 219():82-94. PubMed ID: 37778659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deep generative models for ligand-based de novo design applied to multi-parametric optimization.
    Perron Q; Mirguet O; Tajmouati H; Skiredj A; Rojas A; Gohier A; Ducrot P; Bourguignon MP; Sansilvestri-Morel P; Do Huu N; Gellibert F; Gaston-Mathé Y
    J Comput Chem; 2022 Apr; 43(10):692-703. PubMed ID: 35218219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Machine learning approaches and their applications in drug discovery and design.
    Priya S; Tripathi G; Singh DB; Jain P; Kumar A
    Chem Biol Drug Des; 2022 Jul; 100(1):136-153. PubMed ID: 35426249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Artificial Intelligence-Enabled De Novo Design of Novel Compounds that Are Synthesizable.
    Bhisetti G; Fang C
    Methods Mol Biol; 2022; 2390():409-419. PubMed ID: 34731479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Artificial intelligence and machine learning-aided drug discovery in central nervous system diseases: State-of-the-arts and future directions.
    Vatansever S; Schlessinger A; Wacker D; Kaniskan HÜ; Jin J; Zhou MM; Zhang B
    Med Res Rev; 2021 May; 41(3):1427-1473. PubMed ID: 33295676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Artificial intelligence to deep learning: machine intelligence approach for drug discovery.
    Gupta R; Srivastava D; Sahu M; Tiwari S; Ambasta RK; Kumar P
    Mol Divers; 2021 Aug; 25(3):1315-1360. PubMed ID: 33844136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. De novo drug design by iterative multiobjective deep reinforcement learning with graph-based molecular quality assessment.
    Fang Y; Pan X; Shen HB
    Bioinformatics; 2023 Apr; 39(4):. PubMed ID: 36961341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Artificial intelligence in drug design.
    Zhong F; Xing J; Li X; Liu X; Fu Z; Xiong Z; Lu D; Wu X; Zhao J; Tan X; Li F; Luo X; Li Z; Chen K; Zheng M; Jiang H
    Sci China Life Sci; 2018 Oct; 61(10):1191-1204. PubMed ID: 30054833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.